A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers.
Harada G, Santini FC, Wilhelm CJ, Repetti RW, Chang JC, Yang SR, Lin YT, Moses KA, Falcon C, Goldstein M, Makhnin A, Ginsberg MS, Plodkowski AJ, Kris MG, Drilon A.
Harada G, et al. Among authors: repetti rw.
JTO Clin Res Rep. 2025 Jun 5;6(8):100857. doi: 10.1016/j.jtocrr.2025.100857. eCollection 2025 Aug.
JTO Clin Res Rep. 2025.
PMID: 40687931
Free PMC article.